First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.
TRAX · First Tracks Biotherapeutics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since Apr 6, 2026; less than a full year is stored.
Latest documents
First Tracks Bio reported AMB033 produced statistically significant celiac gluten-challenge results across histology and patient-reported symptoms, and committed to late-stage celiac trials in 2027. The healing-cohort readout is expected in the first quarter of 2027.
First Tracks said its CD122 antagonist produced best-in-class celiac challenge results, plans four indications and late-stage celiac trials in 2027, and reported over $350 million in cash.
First Tracks Biotherapeutics said ANB033’s Phase 1b celiac Cohort 1 met histologic and symptom endpoints, with placebo-adjusted Vh:Cd improvement of +0.49 (p=0.009) and IEL reduction of -20.03 (p<0.001). Cash and cash equivalents totaled $155.6 million as of September 30, 2026.
First Tracks Biotherapeutics said ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a celiac disease Phase 1b cohort. It also completed a $200 million private placement, resulting in $343 million pro forma cash.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TRAX
this stock
First Tracks Biotherapeutics, Inc.
|
$1.87B | — | — | — | 12.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$136.01B | +18.3% | +46.2% | 34.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$97.81B | +22.5% | +20.8% | 20.9 | 2.1% |
|
MRNA
Moderna, Inc.
|
$79.63B | +567.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.15B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 17, 2026
- This year
- 19
First Tracks said its lead celiac drug nearly prevented gluten-driven villous damage in a challenge study. Its second celiac trial, in more severe patients, reads out in the first quarter of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TRAX | -11.9% | +4.0% | +178.8% | -1.3% | — |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | -8.0% | +9.6% | +182.3% | +2.1% | — |